Insider Transactions in Q3 2022 at Cvs Health Corp (CVS)
Insider Transaction List (Q3 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 12
2022
|
Jeffrey R. Balser Director |
BUY
Grant, award, or other acquisition
|
Direct |
406
+39.42%
|
-
|
|
Aug 31
2022
|
Sreekanth K Chaguturu EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,735
+50.0%
|
-
|
|
Aug 31
2022
|
Tilak Mandadi EVP, Chief DDAT Officer |
BUY
Grant, award, or other acquisition
|
Direct |
99,847
+50.0%
|
-
|
|
Aug 31
2022
|
Prem S Shah EVP and Group President |
BUY
Grant, award, or other acquisition
|
Direct |
20,376
+50.0%
|
-
|
|
Aug 04
2022
|
Alan Lotvin EVP&President-PharmacyServices |
SELL
Open market or private sale
|
Direct |
22,541
-17.11%
|
$2,344,264
$104.0 P/Share
|
|
Aug 04
2022
|
Alan Lotvin EVP&President-PharmacyServices |
BUY
Exercise of conversion of derivative security
|
Direct |
22,541
+14.61%
|
$1,397,542
$62.21 P/Share
|
|
Aug 03
2022
|
Daniel P Finke EVP/Pres, Health Care Benefits |
SELL
Open market or private sale
|
Direct |
9,546
-22.89%
|
$954,600
$100.0 P/Share
|
|
Aug 03
2022
|
Daniel P Finke EVP/Pres, Health Care Benefits |
BUY
Exercise of conversion of derivative security
|
Direct |
9,546
+18.63%
|
$496,392
$52.37 P/Share
|
|
Aug 03
2022
|
Alan Lotvin EVP&President-PharmacyServices |
SELL
Open market or private sale
|
Direct |
120,899
-35.41%
|
$11,848,102
$98.0 P/Share
|
|
Aug 03
2022
|
Alan Lotvin EVP&President-PharmacyServices |
BUY
Exercise of conversion of derivative security
|
Direct |
120,899
+26.09%
|
$6,770,344
$56.26 P/Share
|